Texas Biotech negotiating with Genentech to keep argatroban license; NDA deadline will not be met.
Executive Summary
TEXAS BIOTECH RENEGOTIATING ARGATROBAN LICENSING WITH GENENTECH: the agreement as it now stands returns rights for Novastan (argatroban) to Genentech if Texas Biotechnology does not file an NDA by June 30 unless "there is good cause to delay such filing." The NDA will not be filed this year. The agreement, signed in May 1993, covers Canada and the U.S. Genentech licensed the antithrombolytic agent argatroban from Mitsubishi, which manufactures the drug for TBC.